BIOPHYTIS S.A. Biophytis S.A. Share Price Euronext Paris
Equities
ALBPS
FR0012816825
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.85 EUR | 0.00% |
|
+1.19% | -58.33% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 4.6M 4.96M 414M | Sales 2025 * | 18.2M 19.62M 1.64B | Capitalization | 2.35M 2.53M 211M |
|---|---|---|---|---|---|
| Net income 2024 * | -17M -18.33M -1.53B | Net income 2025 * | -8M -8.63M -720M | EV / Sales 2024 * | 0.51 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.13 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 40.58% |
More Fundamentals
* Assessed data
Biophytis S.A. is a biotechnology company in the clinical stage specialized in the development of drug candidates to slow degenerative processes and improve functional capacity in patients with age-related diseases, including respiratory failure in patients suffering from COVID-19.
The company is located in Paris, France and Cambridge, Massachusetts.
| 1st Jan change | Capi. | |
|---|---|---|
| +3.23% | 108B | |
| +10.30% | 105B | |
| +1.57% | 23.46B | |
| -12.92% | 21.72B | |
| -7.05% | 18.64B | |
| -37.64% | 17.45B | |
| -7.19% | 17.19B | |
| +5.94% | 13.99B | |
| +36.84% | 12.53B |
- Stock Market
- Equities
- ALBPS Stock
- ALBPS Stock